Explore why patients with myeloproliferative neoplasmss have unique PCI risks. Learn how to improve post-procedure care.

Gain-of-function mutations in JAK2 exon 12 and in the thrombopoietin receptor are observed in some patients with JAK2V617F-negative myeloproliferative disorders (MPD), suggesting constitutive ...

IFN-α2 (in most centers today pegylated IFN-α2 [Peg-IFN-α2]) induces major or complete molecular remissions in a subset of JAK2V617-positive patients with essential thrombocythemia (ET) and ...

In a randomized phase 3 trial, the combination of the BET inhibitor pelabresib with the JAK inhibitor ruxolitinib resulted in a significantly higher spleen volume reduction from baseline versus ...

Clinical trials offer a unique treatment experience when you live with myeloproliferative disorders. Lower cost of care, direct access to a specialized MDS medical team, and the opportunity to try ...

Incyte’s The Unseen Journey illustrates the hidden emotional and physical toll of myeloproliferative neoplasms (MPNs), a ...

People who use metformin are less likely to develop a myeloproliferative neoplasm (MPN) over time, indicating that the treatment may help prevent the development of certain types of cancers ...

A new study accessed the Mayo Clinic database to investigate the long-term survival of patients with myeloproliferative ...

GLP-1 RA use linked to lower risks for myelodysplastic syndromes, myeloproliferative neoplasms compared with metformin ...